Research Progress of Peroxisome Proliferator-Activated Receptor in Non-Alcoholic Steatohepatitis

Yida Zhou; Ming Chu

doi:10.54097/z2v0ps04

Authors

Yida Zhou
Ming Chu

DOI:

https://doi.org/10.54097/z2v0ps04

Keywords:

NASH, PPAR, PPAR agonists.

Abstract

Non - alcoholic steatohepatitis represents a clinical - pathological syndrome. It is marked by the excessive buildup of fat within liver cells, which occurs due to diverse reasons and in the absence of a history of excessive alcohol intake. This condition leads to fatty degeneration and inflammation of liver cells, and may eventually progress to liver cirrhosis or even hepatocellular carcinoma. The incidence of non - alcoholic steatohepatitis has been on the rise annually and has emerged as a significant factor prompting liver transplantation. A large number of research findings indicate that the peroxisome proliferator - activated receptor (PPAR) is of great significance in the onset and development of non - alcoholic steatohepatitis. PPAR is a nuclear transcription factor that includes three subtypes: PPARα, PPARγ, and PPARβ. PPAR exerts multiple functions in the human body, including metabolic regulation, immune modulation, anti-inflammation, and therapy. Therefore, PPAR agonists can have therapeutic effects on non-alcoholic steatohepatitis by promoting hepatic lipid metabolism, reducing total cholesterol levels in the blood, and inhibiting inflammatory responses. Drugs such as fenofibrate and pioglitazone have been widely used in this regard. This article offers a comprehensive review of the research advancements regarding PPAR in non - alcoholic steatohepatitis. By doing so, it aims to lay a theoretical foundation for the exploration and development of novel medications designed to treat non - alcoholic steatohepatitis.

Downloads

Download data is not yet available.

References

[1] Komeili-Movahhed T, Bassirian M, Changizi Z, Moslehi A. SIRT1/NFκB pathway mediates anti-inflammatory and anti-apoptotic effects of rosmarinic acid on in a mouse model of nonalcoholic steatohepatitis (NASH) J Recept Signal Transduct Res. 2022;42(3):241–250. doi: 10.1080/10799893.2021.1905665.

[2] Komeili Movahhed T, Moslehi A, Golchoob M, Ababzadeh S. Allantoin improves methionine-choline deficient diet-induced nonalcoholic steatohepatitis in mice through involvement in endoplasmic reticulum stress and hepatocytes apoptosis-related genes expressions. Iran J Basic Med Sci. 2019;22(7):736–744. doi: 10.22038/ijbms.2019.33553.8012.

[3] Lee JM, Wagner M, Xiao R, Kim KH, Feng D, Lazar MA, et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature. 2014;516(7529):112–115. doi: 10.1038/nature13961.

[4] "PPARβ/δ suppresses NF-κB-mediated inflammation in skeletal muscle cells by disrupting DNA binding of RelA/p65." (Reference: PLoS One. 2012;7(4): e35822.)

[5] Francque, S., et al. "Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors." Nature Reviews Gastroenterology & Hepatology (2020).

[6] Mirza, A., I. Althagafi, and H. Shamshad. "Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications." European journal of medicinal chemistry (2019).

[7] Ichiro Takada & Makoto Makishima (2020) Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present), Expert Opinion on Therapeutic Patents, 30:1, 1-13, DOI: 10.1080/13543776.2020.1703952

[8] Mirza, A., I. Althagafi, and H. Shamshad. "Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications." European journal of medicinal chemistry (2019).

[9] Kamata S, Honda A, Ishii I. Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease. Biomolecules. 2023 Aug 18;13(8):1264. doi: 10.3390/biom13081264. PMID: 37627329; PMCID: PMC10452531.

[10] Nakamura A, Kagaya Y, Saito H, Kanazawa M, Sato K, Miura M, Kondo M, Endo H. Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study. J Atheroscler Thromb. 2023 Jun 1;30(6):698-699. doi: 10.5551/jat.ER63659. Epub 2023 May 2. Erratum for: J Atheroscler Thromb. 2023 May 1;30(5):443-454. PMID: 37150612; PMCID: PMC10244067.

[11] Yamasaki D, Kawabe N, Nakamura H, et al. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα‐independent mechanisms. Eur J Cell Biol. 2011; 90:657‐664. doi: 10.1016/j.ejcb.2011.02.005

[12] Behl, T., et al. "Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends." Molecules (2022).

[13] Kwon HJ,et al.Traditional Chinese Medicine improves dys-function of peroxisome proliferator-activated receptoraandmicrosomal triglyceride transferprotein on abnormalities inlipid metabolism in ethanol-fed rats.BioFactors,2005,23:163-176.

[14] RATZIU V, HARRISON SA, FRANCQUE S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-a and-, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]Gastroenterology, 2016,150(5):1147-1159.e5.

[15] Tan, C. K., Y. Zhuang, and W. Wahli. "Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome." Expert Opinion on Therapeutic Targets (2017).

[16] Landreth GE, Heneka MT.Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease[J]. Neurobiol Aging, 2001, 22(6): 937-944.

[17] BABAI S, AUCLERT L, LE-LOUT H. Safety data and withdrawal of hepatotoxic drugslJ]. Therapie, 2021, 76(6):715-723.

[18] HELLEMANS K, MICHALIK L, DITTIE A, et al. Peroxisome proliferator-activated receptor-beta signalingcontributes to enhanced proliferation of hepatic stellate cells[J]. Gastroenterology,2003, 124(1):184-201.

[19] GRAHAM DJ, DRINKARD CR, SHATIN D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone[J]. Am J Gastroenterol, 2003, 98(1):175-179.